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Abstract
Inadequate bone volume at the implant recipient site presents a clinical challenge for 
many dental practitioners. To overcome these problems, several approaches have been 
developed and are currently used, including bone grafting strategies and distraction 
osteogenesis. Mesenchymal stem cells (MSCs) have gained their popularity within the last 
two decades, with regard to promising clinical results in improving the bone architecture 
at the implant recipient site. The aim of this chapter was to briefly outline the accessibility 
properties, differentiation capacities, isolation, and characterization of MSCs with regard 
to optimizing bone volume in dental implantology. Additionally, potential benefits and 
pitfalls are discussed in comparison with the conventional bone augmentation techniques.
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1. Introduction
Dental implant therapies became an integral part of the daily dental practice. The success rate 
of implants is related to the correct position and angulation of implants in residual crest, so 
that height and thickness of bone augmentation can allow predictable results [1]. Therefore, 
the qualitative and quantitative characteristics of the surrounding tissues at the implant recip-
ient site play a key role in the success of the procedure. Systemic diseases such as osteoporo-
sis, changes in vitamin D metabolism, diabetes and adverse pregnancy outcomes, and local 
factors such as periodontitis, infections, pre-existing cysts or tumors, and traumatic extrac-
tions might result in the loss of both alveolar bone volume and quality and complicates the 
feasibility and long-term clinical outcomes of dental implant rehabilitation.
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Various reconstructive surgical interventions could be necessary to regenerate bone defects 
prior to implant placement. In the literature, there are numerous clinical and experimen-
tal studies presenting techniques with different results that overcome the problems related 
to the insufficient bone volume at the edentulous alveolar ridge. Among these, the mostly 
performed surgical procedures to obtain bone augmentation are guided bone regeneration 
techniques via synthetic materials, xenografts or allografts, distraction osteogenesis of the 
alveolus, and the augmentation with autogenous bone blocks, which is thought to be the gold 
standard to obtain accurate bone volume and morphology with long-term predictable results. 
All techniques described above have their own advantages and pitfalls.
2. Conventional bone grafting strategies
2.1. Synthetic bone graft materials
A variety of artificial bone substitutes were used to reconstruct bone defects of the jaws. 
Synthetic bone grafts at most possess only osseoconductive characteristics and ideally should 
be biocompatible, show minimal fibrotic reaction, undergo remodeling, support new bone 
formation, and should have a similar strength or similar mechanical characteristics to that of 
the cortical/cancellous bone being replaced [2]. Availability of synthetic bone graft materials 
would eliminate the need for invasive graft-harvesting procedure and the dangers of patho-
gen transmission from immunogenic reaction to bank bone [2, 3]. In the maxillofacial recon-
struction, the mostly used synthetic bone graft materials are:
• calcium phosphates,
• calcium phosphate cements,
• beta-tricalcium phosphates,
• synthetic hydroxyapatites,
• coralline hydroxyapatites, and
• bioactive glasses.
It is obvious that synthetic bone substitutes only have osteoconductive properties, and there is 
a need for improvement in their mechanical and degradation properties to ensure the replace-
ment of the graft material with the living bone.
2.2. Allografts
The term allograft describes transplants between two subjects of the same species. Complications 
associated with the harvesting of autogenous bone have led to gain in their popularity as a 
treatment option in maxillofacial reconstruction. Allografts might offer the same characteris-
tics as autograft; however, they do not present same osteogenic cells and therefore fulfill only 
the demand of osteoconductivity and serve mostly as a scaffold for new bone formation [2]. 
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The advantages of allografts include availability and avoidance of morbidity associated with 
autogenous bone graft harvesting.
It is obvious that tissue safety is a major concern in transplantation. The major risk and 
disadvantage related to the use of allografts are the transmission of infectious agents from 
donor to recipient, which could result in microbial contamination from an infected donor, 
during collection of the tissue from donors or the environment and during processing of the 
tissues [4].
Viral transmission is a potential risk that is historically and serologically reported in asso-
ciation with allografts. Despite the exceedingly low risk, the transmission of human immu-
nodeficiency virus (HIV-1) from seronegative cadaveric donors has reported in Refs. [4, 5]. 
During the history of allogenic tissue transfer, many sterilization techniques have been used 
to prevent infection through allografts which include gamma irradiation, ethylene oxide gas, 
thermal treatment with moist heat, beta-propiolactone, chemical processing, and antibiotic 
soaks [4]. Among these, gamma irradiation offers a clear advantage in terms of safety com-
pared with other sterilization techniques.
2.3. Xenografts
Xenograft is a term used to describe a surgical graft of tissue from one species to an unlike 
species such as coral, bovine, and porcine and are used as calcified matrices generally. The 
processing of xenografts is reported to remove organic components such as cells and protein-
aceous materials, leaving an inert absorbable bone scaffold, which assists in revascularization, 
osteoblast migration, and new bone formation [2, 6].
The use of xenografts has been demonstrated to be effective for increasing bone height and 
bone volume especially in sinus augmentation procedures (Figure 1). Xenogeneic bone is 
available in greater supply and larger sizes, and their physical properties are comparable to 
human cancellous bone [2, 6–8]. In the literature, it has been suggested that the resorption of 
xenografts and their replacement with new bone appears to be slow [9] and consideration 
must be given to the risk of cross contamination with bovine spongiform encephalopathy or 
porcine endogenous retroviruses [10].
2.4. Autografts
In the reconstruction of bony defects of the jaws, autogenous cancellous bone grafts are stated 
to be the most effective bone graft material considering their osteoinductive effects and pre-
dictable long-term results. Autogenous bone contains all of the elements necessary to promote 
vital bone formation, including mineral, collagen matrix, growth factors, and particularity 
vital cells [2]. Following the transplantation, few mature osteoblasts survive the procedure, 
but adequate numbers of precursor cells which have the osteogenic potential remain [2, 11]. 
Considering the bone volume needed, the donor sites for the reconstruction of the defects of 
the jaws are anterior or posterior iliac crest, mandibular ramus, mandibular symphysis, tibia, 
and parietal bone.
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Limitations of the use of autogenous bone graft harvesting differ from the selected donor 
site, however, are mostly related to the so-called “donor site morbidity.” The complications 
related to bone graft harvesting are [12]:
• increased operative time,
• limited availability and significant morbidity related to the intraoperative blood loss,
• wound complications,
Figure 1. Augmentation of the atrophic posterior maxilla (a) The insufficent bone volume at the right posterior maxilla. 
(b) Intraoral clinical view (c) Sinus bone grafting with xenograft (Bioss®, Geistlich Germany). Implants were inserted 
simultaneously with sinus membrane elevation. (d) Panoramic radiograph after 1 year.
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• possible neurosensory alterations at the harvesting site, and
• chronic pain which is mainly attributed to the dissections performed during the graft 
harvesting.
An ultimate bone formation occurs only as a consequence of osteogenic/osteoinductive/osteo-
blastic cellular activity. In recent years, experimental studies followed by successfully clinical 
series have led to gaining the popularity of osteogenic precursors such as mesenchymal stem 
cells (MSCs) in bony reconstruction of the defects of the jaws and added a new dimension to 
the bone-gaining procedures in dental implantology.
The aim of this chapter was to describe the isolation methods regarding the MSCs used in 
oral implantology and briefly describe their clinical applications in peri-implantary surgical 
interventions.
3. Mesenchymal stem cells
Stem cells are unspecialized cells with the ability to proliferate and differentiate to multiple 
cell types when stimulated by both internal and external signals. They can be either embry-
onic stem cells, which are found in blastocysts or adult stem cells, which are called as plu-
ripotent cells and can be found in bone marrow in the form of hematopoietic, endothelial, 
and MSCs.
The first successful isolation of bone marrow MSCs, then called colony-forming fibroblast-like 
cells, was described in 1968 by Friedenstein et al. [13] Today, MSCs are defined as nonhemato-
poietic progenitor cells that have the ability to differentiate into distinct mesodermal lineages 
(adipogenic, chondrogenic, osteogenic, or myogenic), which can produce bone, cartilage, fat, 
or fibrous connective tissue depending on their differentiation process [14].
Sources of MSCs in adult patients are [15, 16]:
• bone marrow [16] (Figure 2),
• peripheral blood [17],
• adipose tissue [18],
• muscle [19],
• periosteum [20],
• synovium [21], and
• teeth (perivascular niche of dental pulp and periodontal ligament) [22].
Since the first description of MSCs, various studies aimed to identify an ideal source for MSC 
harvesting. In 2006, Zhu et al. [23] have performed a study on the investigation of donor 
cell-related differences in tissue-engineered bone and examined bone marrow MSCs, alveolar 
bone cells, and periosteal cells for their in vivo potential to form bone.
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They have demonstrated that periosteal cells are the best choice for enhancing bone for-
mation in tissue engineering of bone regeneration. In addition, recent studies showed a 
lower osteogenic differentiation potential of adipose tissue–derived stromal cells (ASCs) 
compared to bone marrow–derived mesenchymal stromal cells. According to Açil et al. 
[24], a careful reconsideration of the use of ASCs in bone tissue engineering application 
should be given.
3.1. Characterization of mesenchymal stem cells
Surface antigen expression, which allows for a rapid identification of a cell population, has 
been extensively used in experimental studies focusing on the identification of MSCs. For 
analysis of surface antigen expression, flow cytometry analysis and immunocytochemistry are 
efficient methods that reveal the marker profile of individual cells. In addition, fluorescence-
activated cell sorting (FACS) is a valuable protocol for sorting isolation of MSCs. (Figure 3)
All techniques described above rely on both positive and negative selection by cell antigen 
surface markers, as well as physical properties of cells such as forward and side scatter char-
acteristics [25].
According to the Mesenchymal and Tissue Stem Cell Committee of the International Society 
for Cellular Therapy [26], minimal criteria to define human MSCs are as follows:
• MSC must be plastic-adherent when maintained in standard culture conditions.
Figure 2. Bone marrow aspiration.
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• MSC must express CD105, CD73, and CD90 and lack expression of CD45, CD34, CD14 or 
CD11b, CD79a, or CD19 and human leukocyte antigen-D-related (HLA-DR) surface molecules.
• MSC must differentiate to osteoblasts, adipocytes, and chondroblasts in vitro.
Since the first description of the above mentioned criteria by Mesenchymal and Tissue Stem 
Cell Committee of the International Society for Cellular Therapy in 2006, many studies have 
investigated the surface antigen expression of human MSCs in order to increase the confi-
dence in their identification and verification. Lee et al. [27] have demonstrated that CD14, 
CD31, CD34, CD45, CD49d, CD49f, CD51, CD54, CD71, CD106, CD133, major histocompat-
ibility complex (MHC II), cytokeratin, and desmin were absent from human MSCs, whereas 
CD13, CD29, CD44, CD59, CD73, CD90, CD105, CD166, MHC I,a-SMA, and vimentin were 
present on human MSCs. For human bone marrow stromal cells, common targets of nega-
tive antigene expression include CD2, CD3, CD11b/Integrin alpha M, CD14, CD15/Lewis X, 
CD16/F
c
gamma RIII, CD19, CD38, CD56/NCAM-1, CD66b/CEACAM-8, CD123/IL-3 R alpha, 
and CD235a/Glycophorin.
For the positive selection of MSCs, CD271/NGF R, CD105/Endoglin, STRO-1, ganglioside 
GD2, and SUSD2 are relatively newly identified surface markers. In addition, STRO-1, CD271, 
CD200, ganglioside GD2, and frizzled-9 tissue non-specific alkaline phosphatase (TNAP) are 
suggested to be the latest markers used to verify MSC Identity [28, 29]. Identification of both 
positive and negative novel antigen surface markers would lead to modifications in the future.
Figure 3. Morphology of MSCs obtained from bone marrow transfected with fluorescent protein. (Scale 100 μm).
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4. Current concepts in mesenchymal stem cell harvest
4.1. Periodontal ligament
Shi et al. [14] have showed that periodontal ligament regeneration involves the recruitment 
of progenitor cells or stem cells, differentiating into either fibroblasts, cementoblasts, or 
osteoblasts, securing the teeth in the sockets between the cementum and adjacent alveolar 
bone. Seo et al. [30] have isolated stem cells from periodontal ligament for the first time 
and gave us new strategy to reconstruction of periodontium. According to Seo et al. [30], 
periodontal ligament stem cells (PDLSCs) share similar characteristics with other adult 
stem cells, including the ability to self-renew and multi-lineage differentiation potential. 
All these results suggested that PDLSCs might belong to a unique population of postnatal 
mesenchymal cells.
A literature survey could reveal that third molar teeth were mostly used for PDLSC isola-
tion. Briefly [31], impacted third molars were surgically extracted, and periodontal dental 
ligament was gently scraped from the middle root surface. Coronal and apical portions of 
the ligament were not used in order to avoid contamination by gingival and pulpal cells. 
Periodontal dental ligament tissues were then minced then digested in a solution contain-
ing 3 mg/ml collagenase type I and 2.5 mg/ml dispase II for 1 h at 37°C. After digestion, 
tissue was seeded into culture flasks with alpha-modification of Eagle’s Medium supple-
mented with 10% fetal bovine serum, 2-mM Glutamine, 100-U/mL penicillin and 100-μg/mL: 
streptomycin solution at 37°C in 5% CO
2
 in a humidified atmosphere. After single cells were 
attached on the plastic bottom of the flask, non-adherent cells were removed by changing the 
medium [31].
Hakki et al. [32] have suggested that BMP-2, -6, and -7 are potent regulators of periodon-
tal ligament stem cell gene expression and bio mineralization. BMPs with periodontal liga-
ment stem cell isolated from periodontal ligament tissues provide a promising strategy for 
bone tissue engineering. According to a recent study performed by Açil et al. [51], BMP-7 
triggers periodontal dental ligament cells to differentiate toward an osteoblast/cementoblast 
phenotype.
4.2. Adipose tissue
According to Açil et al. [24], ASCs could be easily isolated by using the modified technique that 
has been previously described by Zuk et al. [33]. Briefly description of the technique is; the adi-
pose tissue, which could be obtained from liposuction procedures or from the subcutaneous tis-
sue at the surgical access to the iliac crest during reconstructive maxillofacial surgical procedures.
Recent studies indicated a lower osteogenic differentiation potential of ASCs compared to 
bone marrow–derived mesenchymal stromal cells. As we have mentioned before, Açil et al. 
[24] have evaluated the effects of potent combinations of highly osteogenic BMPs in order to 
enhance the osteogenic differentiation potential of ASCs and indicated a restricted osteogenic 
differentiation potential of ASCs and suggest careful reconsideration of their use in bone tis-
sue engineering applications.
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4.3. Bone marrow
The superior iliac crest is usually preferred as a donor site due to its ease in access and trabecu-
lar structure. As described by Hernigou et al. [34] and later by Shapiro et al. [35], briefly, appro-
priate local anesthesia of the skin and subcutaneous soft tissues should be administered. Then, 
a 1-cm stab incision was performed over iliac crest. An 11-gauge, 11-cm Jamshidi needle was 
used to aspirate the bone marrow. Effort was taken to use a parallel approach, with the needle 
directed parallel to the iliac wing between the inner and outer tables, and the needle was subse-
quently withdrawn and repositioned [34, 35] (Figure 4). The marrow aspirates was then passed 
through a sterile filter into a separate compartment to remove particulate matter. The material 
was transferred for centrifugation resulting marrow cell concentration [34, 35].
Recent literatures have showed the potential benefits of using a cocktail of mononuclear cells 
without expanding them in vitro before reimplantation [36] (Figure 5). Therefore, there are 
also various systems developed for harvesting of MSCs from bone marrow. One of these is the 
bone marrow–derived MNCs isolation by synthetic poylsaccharid (FICOLL), technique, which 
is currently accepted as the gold standard [36, 37]. The FICOLL method might present a useful 
Figure 4. Bone marrow aspiration from the superior iliac crest.
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technique for hospitals; however, the system is a time-consuming one, and a good manufac-
turing practice (GMP) laboratory is required. To ensure the clinical use in operating facilities 
without GMP possibilities, closed systems such as closed bone marrow aspirate concentrate 
(SmartPReP2 Bone Marrow Aspirate Concentrate System; BMAC; Harvest Technologies 
GmbH) system were developed [38]. Saurbier et al. [36] have compared new bone formation in 
maxillary sinus augmentation procedures using biomaterial associated with MSCs separated 
by FICOLL and BMAC and observed a higher proportion of hard tissue in the BMAC group.
Marx et al. [39] have compared the histologic parameters and outcomes of two types of grafts in 
large vertical maxillary defects: a composite graft of recombinant human bone morphogenetic pro-
tein-2/acellular collagen sponge (rhBMP-2/ACS), crushed cancellous freeze-dried allogeneic bone 
(CCFDAB), and platelet-rich plasma (PRP) and size-matched 100% autogenous grafts in 20 patients. 
According to their findings, the composite graft of rhBMP-2/ACS-CCFDAB-PRP regenerates bone 
in large vertical ridge augmentations as predictably as 100% autogenous graft with less morbidity, 
equal cost, and more viable new bone formation without residual nonviable bone particles but with 
more edema which might be attributed to the incisional release of the periosteum intraoperatively.
4.4. Peripheral blood
According to the material and methods of the experimental study performed by Sato et al. [40], 
peripheral blood could be obtained by jugular vein puncture, collected into syringes containing 
0.5-ml sodium heparin and should be transported at 4°C to the laboratory within 3 h. To isolate 
peripheral blood-derived mononuclear cells, undiluted blood layered onto 12-ml Lympholyte 
Figure 5. Diagrammatic illustration of the steps in osteoblast cell culture. Bone particles were obtained, the soft tissues 
were removed, and washed with PBS. The bone particles were minced and placed in culture flasks. After 3–4 weeks in 
incubation, cells have reached confluence.
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in a 50-ml tube and centrifuged at 300 g for 40 min without braking [59]. The mononuclear cells 
were collected and washed twice with phosphate buffered saline (PBS) by centrifuging at 300 g 
for 5 min followed by an additional wash with PBS. After that, cells were re-suspended in culture 
medium which consists of Dulbecco’s modified Eagle’s medium with 5% separated autologous 
plasma, 10% fetal bovine serum and 10-μl/ml 100-units/ml Penicillin/Streptomycin solution. 
Subsequently, cells obtained from each 12 ml of blood were seeded onto a 100-mm2 tissue cul-
ture dishes and incubated in a humidified atmosphere at 37°C with 5% CO
2
. Nonadherent cells 
were removed by washing the mononuclear cells twice with PBS after 72 h of incubation. After 
2 weeks, colonies of adherent fibroblast-like cells could be noticed. When the colony reached the 
approximate size of 5 cm2, cells are detached and seeded in a new flask. The MSCs maintained 
in growth medium until ~70% confluence. The cells were then treated with 0.05% EDTA solu-
tion and could be cultured for subsequent passage in 100 mm2 dishes at 7500 cells/cm2 in base 
medium. This procedure was repeated as many times as possible.
Kassis et al. [41] evaluated the ability of fibrin microbeads (FMB) to separate human MSC 
from different sources other than bone marrow, with special emphasis on granulocyte colony-
stimulating factor (G-CSF)–mobilized peripheral blood of healthy individuals. According to 
their material and methods, fibrin microbeads that bind matrix-dependent cells were pro-
duced from concentrated fibrinogen by a stirred heated oil emulsion technique and used to 
isolate MSC from the mononuclear fraction of mobilized peripheral blood of adult healthy 
human donors treated with G-CSF. Based on their results, FMB may have special advantage 
in isolating MSC from mobilized peripheral blood.
The isolation of MSCs from peripheral blood is a relatively new method with the main advan-
tage of the ease in access, and further studies are needed to clarify the most appropriate tech-
nique. In addition, the introduction of platelet aggregates in oral and maxillofacial surgery 
has changed the approach toward extensive reconstruction of resorbed maxillae (Figure 6) 
and mandibles for implant reconstruction [42].
Figure 6. Second generation platelet aggregate (platelet rich fibrin) application in augmentation of the posterior maxilla. 
(a) Elevation of the membrane and preparation of PRF combined with Xenograft (Bioss®, Geistlich Germany) (b) Platelet 
rich fibrin (PRF) and Xenograft in situ. Preparation of the PRF membrane. (c) Placement of the membrane.
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A possible role of platelet aggregates in local regulation of fracture healing and bone regener-
ation was attributed to the synergic effect of growth factors such as isomers of platelet-derived 
growth factor, transforming growth factor A1 and A2, insulin like growth factor > and A, and 
vascular endothelial growth factor. From this point of view, platelet aggregates could help 
in the differentiation and chemotactic and mitogenic stimulation of MSCs, which leads to an 
enhancement of bone repair and regeneration. Moreover, Marx [43] have recently confirmed 
that platelet rich plasma (PRF) contains an amount of 250×103 −400×103 per mL, which are 
positive for CD 44, CD 90, CD 105, and CD 34.
5. Mesenchymal stem cells in the reconstruction of the osseous defects of 
the jaws
Tissue-engineering therapy is a recent treatment modality in dental field to rehabilitate quan-
titative and qualitative properties of both soft and hard tissues with the use of cells with 
regenerative potential signaling molecules such as growth factors and a biocompatible matrix 
serving as a scaffold [44, 45].
During the past 2 decades, various experimental studies focusing on the osteogenic prop-
erties of MSCs have been performed. In 2001, Cooper et al. [46] have studied the relation-
ship between bone sialoprotein (BSP) expression and osteocalcin expression with subsequent 
osteogenesis occurring in MSC-based implants and suggested that culture-expanded, cryo-
preserved human MSCs have osteogenic potential and demonstrated that implanted cell gene 
expression can reveal the early onset of bone formation.
In 2003, De Kok et al. [47] have evaluated MSC-based alveolar bone regeneration in a canine 
alveolar saddle defect model and observed that equivalent amounts of new bone were formed 
within the pores of the matrices loaded with autologous MSCs or MSCs from an unrelated 
donor, confirming the hypothesis that MSCs have the capacity to regenerate bone within 
craniofacial defects In addition, they have also stated that neither autologous nor allogeneic 
MSCs induced a systemic response by the host. Gutwald et al. [48] compared the osteogenic 
potential of mononuclear cells harvested from the iliac crest combined with bovine bone min-
eral (BBM) with that of autogenous cancellous bone alone and studied bilateral augmenta-
tions of the sinus floor in 6 adult sheep and reported that MSCs, in combination with BBM as 
the biomaterial, have the potential to form bone.
In the literature, there are also numerous studies focusing on the stimulating effects of various 
growth factors, most notably BMPs, on the osteogenic differentiation of MSCs [49, 50]. Açil et 
al. [51] have compared the most potent growth factors in regard to their osteoinductive poten-
tial and stated that the combined addition of BMP-2, BMP-6, and BMP-9 to the osteoinductive 
culture medium containing dexamethasone, β-glycerophosphate, and ascorbate-2-phosphate 
produces more potent osteoblast differentiation of human MSCs in vitro.
Following various experimental studies, the number of the clinical prospective studies has 
also increased steadily, and good cases of translational research from basic research to clinical 
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application have arisen. In a groundbreaking study, Wiltfang et al. [52] have reconstructed 
a mandibular discontinuity defect after ablative surgery using the gastrocolic omentum as 
a bioreactor for heterotopic ossification via a titanium mesh cage filled with bone mineral 
blocks, infiltrated with 12 mg of recombinant human BMP2, and enriched with bone marrow 
aspirate. The scaffold was implanted into the gastrocolic omentum, and 3 months later, a 
free flap was harvested to reconstruct the mandibular defect. In vivo single-photon-emission 
computed tomography/computed tomography revealed bone remodeling and mineralization 
inside the mandibular transplant during prefabrication. They have reported that the quality 
of life of the patient significantly increased with acquisition of the ability to masticate and the 
improvement in pronunciation and aesthetics.
It is well known that MSCs can be directed to differentiate into an osteoblastic lineage in 
the presence of growth factors. Furthermore, platelet-rich plasma (PRP), which can be easily 
isolated from whole blood, was often used for bone regeneration, wound healing, and bone 
defect repair [53]. Marx [43] have stated that PRP contains an amount of 250×103 −400×103 per 
ml which are positive for CD 44, CD 90, CD 105, and CD 34.
Yamada et al. [54] investigated as basic research tissue-engineered bone regeneration using 
MSCs and PRP in a dog mandible model and confirmed the correlation between osseointegra-
tion in dental implants and the injectable bone. After that, same authors applied this injectable 
tissue-engineered bone to onlay plasty in the posterior maxilla or mandible in three human 
patient with simultaneous implant placement and reported stable and predictable results in 
terms of implant success [55]. In 2005, Ueda et al. [56] have used MSCs in a clinical study under-
taken to evaluate the use of tissue-engineered bone, MSCs, platelet-rich plasma, and beta-trical-
cium phosphate as grafting materials for maxillary sinus floor augmentation and proclaimed 
that tissue-engineered bone provided stable and predictable results in terms of implant success.
In order to increase the amount of available bone where dental implants must be placed, Filho 
Cerruti et al. [57] evaluated PRP and mononuclear cells (MNCs) from bone marrow aspirate 
and bone scaffold in 32 patients and have concluded that the process of healing observed in the 
patients was due to the presence of mesenchymal stem cell in MNC fraction in the bone grafts. 
Schmelzeisen et al. [58] reported a simplified method of using to regenerate hard tissue and sug-
gested that bone marrow aspirate concentrate combined with a suitable biomaterial can form 
sufficient bone within 3 months for further implants to be inserted and at the same time mini-
mize morbidity at the donor site. Similarly, Ricket et al. [59] have assessed whether differences 
occur in bone formation after maxillary sinus floor elevation surgery with bovine bone mineral 
mixed with autogenous bone or autogenous stem cells and stated that MSCs seeded on bovine 
bone mineral particles can induce the formation of a sufficient volume of new bone to enable 
the reliable placement of implants within a time frame comparable with that of applying either 
solely autogenous bone or a mixture of autogenous bone and bovine bone mineral particles.
Not only the defects at implant recipient sites, peri-implantar bone loss has also become a 
point of interest for some researchers, and efforts have been made over the last few decades 
to produce reliable and predictable methods to stimulate bone regeneration in bone defects 
resulting from peri-implant diseases [60]. Ribeiro et al. [61] have investigated the effect of bone 
marrow–derived cells associated with guided bone regeneration in the treatment of dehiscence 
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bone defects around dental implants and suggested that bone marrow–derived cells provided 
promising results for peri-implantar bone regeneration, although the combined approach 
seems to be relevant, especially to bone formation out of the implant threads. Similarly, Kim et 
al. [62] evaluated the potential of periodontal ligament stem cells and bone marrow stem cells 
on alveolar bone regeneration in a canine peri-implant defect model and demonstrated the 
feasibility of using stem cell–mediated bone regeneration to treat peri-implant defects.
6. Conclusion
A growing number of studies indicate that stem applications are feasible protocols with clin-
ically successful results in restoration of the bone architecture of the maxillofacial region. 
Composite grafts of MSCs, BMP, PRP, and bone graft combinations are able to achieve clinical 
results equivalent to autogenous grafts in large vertical ridge augmentations without donor 
bone harvesting.
Continued and extended experimental studies are needed to exactly determine the isolation, 
characterization, and differentiation properties of MSCs. In addition, development of chair-
side protocols would be beneficial in order to adapt MSC applications to the daily dental 
practice.
Abbreviations
ASC Adipose tissue-derived stromal cells
BMAC Bone marrow aspirate concentrate
BMP Bone morphogenetic protein
CCFDAB Crushed cancellous freeze-dried allogeneic bone
CD Cluster of differentiation
CEACAM Carcinoembryonic antigen-related cell adhesion molecule
FACS Fluorescence-activated cell sorting
FMB Fibrin microbeads
GMP Good manufacturing practice
HIV Human immunodeficiency virus
HLA-DR Human leukocyte antigen-D-related
MHC Major histocompatibility complex
MSC Mesenchymal stem cell
NCAM Neural cell adhesion molecule
PBS Phosphate buffered solution
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PDLSC Periodontal ligament stem cell
PRF Platelet rich plasma
PRP Platelet-rich fibrin
rhBMP Recombinant human bone morphogenetic protein
TNAP Tissue non-specific Alkaline Phosphatase
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